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Alzheimer’s disease (AD) is the most common dementia in the industrialized world, with prevalence rates well over
30% in the over 80-years-old population. The dementia causes enormous costs to the social healthcare systems, as
well as personal tragedies for the patients, families and caregivers. AD is strongly associated with Amyloid-beta (Aβ)
protein aggregation, which results in extracellular plaques in the brain, and according to the amyloid cascade
hypothesis appeared to be a promising target for the development of AD therapeutics. Within the past decade
convincing data has arisen positioning the soluble prefibrillar Aβ-aggregates as the prime toxic agents in AD.
However, different Aβ aggregate species are described but their remarkable metastability hampers the identification
of a target species for immunization. Passive immunotherapy with monoclonal antibodies (mAbs) against Aβ is in
late clinical development but recently the two most advanced mAbs, Bapineuzumab and Solanezumab, targeting
an N-terminal or central epitope, respectively, failed to meet their target of improving or stabilizing cognition and
function. Preliminary data from off-label treatment of a small cohort for 3 years with intravenous polyclonal
immunoglobulins (IVIG) that appear to target different conformational epitopes indicate a cognitive stabilization.
Thus, it might be the more promising strategy reducing the whole spectrum of Aβ-aggregates than to focus on a
single aggregate species for immunization.
Keywords: Passive immunization, Dementia, Therapeutic antibodies, Effector function, Oligomers, ADDLs,
Protofibrils, Regulatory strategyAß-aggregates and their impact in choosing the
right antibody
Alzheimer's disease (AD) is the most common form of de-
mentia. It accounts for 60-70% of all cases among the
oldest old [1]; and countries in demographic transition will
experience the greatest growth. AD is a multifactorial dis-
ease with pathogenic cerebral protein aggregation, includ-
ing aggregation of hyperphosphorylated tau (phospho-tau)
and the aggregation and deposition of Amyloid-β (Aβ), ac-
companied by oxidative stress and glial activation [2].
Thus, many pathophysiological pathways coexist, resulting
in synaptic dysfunction and severe neuronal loss that
cause deterioration and finally loss of memory and cogni-
tion. Within the past two decades substantial efforts have
been made to elucidate the toxic nature of Aβ in AD. The* Correspondence: zimmermann@hochschule-bc.de
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reproduction in any medium, provided the orprimary event that induces the abnormal accumulation of
Aβ is the dysregulated proteolytic processing by secretases
of its parent molecule, the amyloid precursor protein
(APP) [3]. Dysregulated APP-processing results in the Aβ-
peptide of predominantly 39 to 43 residues, but even
smaller species occur. Further post-translational modifica-
tions result in a various number of N- and C-terminal var-
iants of the Aβ-peptide [4], increasing heterogeneity and,
thus, the number of possible targets.
The aggregation of Aβ species is thought to play a piv-
otal role in the disease progression of AD through a cas-
cade of events, called the amyloid cascade hypothesis
[5-7]. In the light of the recent clinical trials with anti-
Aβ drugs the amyloid cascade hypothesis is again a
subject of discussion.
The self-association of Aβ-peptide results in aggre-
gates with varying morphology and molecular weightLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Pathways of aggregation and observed Aß-aggregate intermediates. Monomeric Aß folds to the activated state and then exists in
rapid equilibrium with low molecular weight oligomers, which aggregate over various transient high molecular weight intermediates to matured
fibrils. The definition of LMW and HMW oligomers is related to the elution profile of Aß-aggregates in size exclusion chromatography, revealing
two predominant peaks at the exclusion limit (>60 kDa) and at the void volume (4-20 kDa), respectively. The HMW intermediates comprise
pentamers, hexamers and multiples thereof, finally forming protofibrils, which are the precursors for multi-stranded ribbons of matured fibrils.
Further neurotoxic aggregate species e.g. AßO, ADDL and ASPD are believed to aggregate over alternative pathways but preliminary data
revealed that these are able to converge into the other pathways of aggregation (inter-conversion). Interestingly, every change in the
experimental paradigm can provoke this aggregate conversion. Therefore, one might assume that many different aggregates coexist and, thus,
neurotoxicity can be attributed to several pathogenic modes of action. Monomers and fibrils are believed to be biologically inert; however fibrils
are able to collapse into protofibrils and then also reveal toxicity. The broad range of prefibrillar aggregates have been reported as
pathophysiologically relevant in AD.
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an activated monomeric state and then exists in rapid
equilibrium with low molecular weight aggregates [8].
These further associate over various transient intermedi-
ates to mature insoluble Aβ-fibrils, which accumulate in
the AD brain as senile plaques. Further investigations fo-
cused on the prefibrillar aggregates, the water-soluble
oligomers, which are increased in AD-patients [9]. How-
ever, the term ”soluble” roughly describes aggregates,
which remain in solution upon centrifugation at 15000 ×
g [10]. Monomeric and fibrillar Aβ are believed to be
biologically inert; however Aß-fibrils can collapse back
into protofibrils in the presence of lipids and then also
reveal toxicity [11]. The oligomeric species show, so far,
the best correlation to neuro-psychiatric analysis and
synapse loss [12-14]. These results increased the impact
of soluble, premature Aβ-aggregates in the disease pro-
gression of AD, which has been positioned in the
reformulated amyloid cascade hypothesis by Selkoe and
Walsh [15]. Huge efforts have been made to identify dis-
tinct Aβ-aggregates derived from synthetic peptide and
natural sources, resulting in a plethora of described Aβ-species with overlapping size and morphology [16]: the
Aβ-dimer [17,18], low-molecular weight oligomers, com-
prising dimeric to tetrameric Aß [19], pentamers and
hexamers [20], the dodecameric Aß56* derived from
transgenic mice and human brain [21,22], globulomers
[23], Aß-oligomers [24], Alzheimer-derived diffusible li-
gands – ADDL [10], protofibrils [25], amylospheroids [26]
just to mention the major Aβ-preparations in the field. A
further complexity comes with the various Aβ-fragments
including the N- and C-terminal truncated Aβ-species.
Some of these different Aβ-preparations have been
used for immunization and screening to generate thera-
peutic monoclonal antibodies (mAbs) which are being
evaluated in preclinical and clinical trials. Literally, the
definitions for all the above-mentioned Aβ-aggregate
species are based on the protocols for Aβ-aggregate
preparation and the methods used for characterization.
These definitions are not strictly used – resulting in
controversy regarding the reported Aβ-species and the
observed patho-physiological effects. It still remains un-
solved whether the reported synthetic Aβ-aggregates
exist in vivo since they are hardly comparable to the
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depth biophysical characterization based on high protein
concentrations and purity however these Aβ-aggregates
have to be critically reviewed since high protein concen-
trations are necessary for their generation. Intriguingly,
endogenous Aβ reveals nanomolar concentrations in the
brain and comprises a heterogeneous peptide-mixture
with post-translational modifications and truncations at
the N- and C-terminus, respectively. Furthermore, the
characterization of natural derived Aβ, e.g. from tissue,
CSF or blood, needs sophisticated methods for extrac-
tion which have an intrinsic effect on the identity of the
Aβ-species and thus eludes a characterization of the ag-
gregates originally present under native conditions. The
common methods used for characterization of endogen-
ous Aβ, e.g. SDS-PAGE, do not resolve the actual aggre-
gative state. Thus, despite the reported presence of
prefibrillar Aβ [27] the debate about the most relevant
Aβ-species is still controversial. The identification of
endogenous Aβ-aggregates is hampered owing to the dy-
namic and non-linear nature of aggregation and meth-
odological limitations [28-30]. To this date the larger
aggregates (e.g. ADDL, AβO) could not be shown
in vivo by means of biophysics to structurally relate
them to endogenous Aβ. Moreover, owing to the meta-
stability and the ability for inter-conversion of different
aggregation pathways, it is questionable whether to focus
on a single “most-toxic” Aβ-species rather than the
whole spectrum of Aβ-aggregates [28]. With regard to
an anti-Aβ therapy, depleting total Aβ including all
various Aβ fragments and aggregative species might be
favorable compared to one conformation or species-
specific antibodies since these might pick only one rogue
out of many.
Aβ immunotherapy with monoclonal antibodies
Although AD has been known about for over 100 years,
there is still only symptomatic treatment available on the
market. According to the amyloid cascade hypothesis,
eradication of Aβ appears to be the aim for any disease-
modifying therapy against AD, a therapy that is desper-
ately needed to deal with the millions of AD patients in
the upcoming decades.
The first active immunotherapy trial (AN-1792) using
aggregated, full-length Aβ42 was halted after 6% of the
patients developed severe meningoencephalitis [31]. The
active vaccination with Aβ42 and adjuvant produced
both a humoral and a cellular response against Aβ
resulting in a strong and in some cases fatal immune re-
sponse against the endogenous peptide Aβ [32].
Consequently, passive immunization as alternative was
considered safer and more controllable than active
immunization (see Table 1 for current trials). The mech-
anism of action of mAbs is firstly the capture of thetarget and secondly the effector function linked to the
Fc domain of the mAb (for review see [33]). But how
can antibodies against Aβ interfere with AD pathology?
Despite the rapid advance of this therapeutic strategy
into clinical trials and the hundreds of research papers,
there still remain enigmatic aspects in Aβ immunother-
apy [2]. Most importantly the mechanism of action is
still not elucidated in rodents, let alone in humans, al-
though many hypotheses have been proposed – includ-
ing microglia-mediated phagocytosis, antibody-mediated
alterations of Aβ aggregation and neutralization of Aβ
toxicity, intracerebral sequestration of Aβ in a mono-
meric state and peripheral sink [34].
Besides the microglial engulfment of Aβ, the other
discussed mechanisms of action rely on binding Aβ and
do not need effector function to clear Aβ. However, the
first-in-class mAbs against Aβ are full IgG1s that
strongly mediate pro-inflammatory effector functions.
But, the Fc-domain of the antibodies can mediate tox-
icity since Aβ is also deposited in cerebral vasculature
forming vascular plaques. In particular ApoE4 (a heredi-
tary risk factor for AD) carriers reveal vascular amyloid
plaques [35]. Anti-Aβ antibodies capable to induce the
complement system can lead to the formation of mem-
brane attack complexes and thereby microbleedings i.e.
microhemorrhages, vasogenic edema or if diagnosed
with magnetic resonance imaging amyloid-related im-
aging abnormalities (ARIA) [36].
Conversely, many conflicting data exists about the
mechanism of action of different epitope-specific anti-
bodies and also about their blood-brain barrier passage
(for review see [33]). Thus, one might assume that more
than a single process takes place in passive Aβ immuno-
therapy. In summary, it appears that clearing cerebral
Aβ, quite irrespective from the mechanism of action, is
needed for improvement in brain pathology, synaptic
transmission and cognition in AD animal models –
given the well-known limitation of AD models.
The most advanced clinical candidates all recognize more
or less linear epitopes on the Aβ peptide. Bapineuzumab
(3D6) recognizes the linear N-terminus of Aβ and binds all
forms of Aβ (e.g. prefibrillar aggregates and plaques)
[37,38]. Recently binding of 3D6 to Aβ-oligomers from an
AD animal model was shown, but could not be confirmed
for CSF from AD patients [39]. Bapineuzumab is believed
to mainly clear Aβ by passing the blood-brain barrier and
subsequent microglial engulfment, sequestration but
also peripheral sink. In Summer 2012, the sponsors of
the Bapineuzumab Phase III clinical trial reported dis-
appointing results and the discontinuation of all but one
subcutaneous clinical trial [40]. In detail, the studies in-
volving ApoE4 carriers and non-carriers failed to show
any significant benefit on cognition or functional per-
formance, even though positive effects on the secondary
Table 1 Passive immunotherapy for AD in clinical Phases, adopted from [33], anti-Aβ antibodies in clinical Phases I - III
mAb Specific for Clinical trials References
Bapineuzumab, humanized
3D6
N-terminus (aa 1-5) Phase III: trials were halted after completion
of two trials demonstrated a failure to meet
primary outcome measures of cognition and




central (aa 16-24), accessible only on
soluble Aβ
Phase III: ongoing as preventive trial in
familial AD (DIAN). Trials failed to meet their
primary endpoints in cognition and activities
of daily living. A subsequent analysis of mild
AD patients pooled from both trials showed




N-terminal (aa 3-12) and C-terminus
(aa 18-27)
Phase III: ongoing in prodromal AD patients
(DIAN), amyloid reduction but also ARIAs






most NAbs-Aβ bind central and C-
terminus as well as pathogenic
conformations of Aβ (focus on
dimers)
Phase III (Gammagard): ongoing, (improved
cerebral glucose metabolism and cognitive
stabilization of AD symptoms was shown in
small clinical studies, too small for statistical
evaluation)
[49-51]
Phase III (Plasmapheresis with infusion of
20% albumin and Flebogamma): ongoing
Phase II (Octagam): cognition endpoints not
met, but improved cerebral glucose
metabolism




oligomeric and protofibrillar forms,
(aa 13-14 appears relevant)
Phase II: ongoing as long-term safety
extension study.
[52]
Preventive trial in an extended family
carrying a presenilin-1 mutation, which
causes early onset AD planned for 2013.
BAN2401, humanized
mAb158
binds large-size Aβ protofibrils
(>100 kDa)
Phase II: ongoing [53,54]
GSK933776 N-terminus of Aβ Phase I: two clinical trials for AD are
completed and one for macular
degeneration is ongoing. Further





N-terminal (aa 1-5) Phase I: ongoing. Lower toxicity (ARIAs)
compared to Bapineuzumab is expected.




protofibrils, and low molecular
weight Aβ
Phase I: ongoing [57]
BIIB037/BART, full human
IgG1
binds insoluble fibrillar human Aβ Phase I: ongoing in prodromal AD patients [58,59]
(aa, amino acid; Aβ, Amyloid-β; ApoE4, ApolipoproteinE4; ARIA, amyloid-related imaging abnormalities; DIAN, Dominantly Inherited Alzheimer Network; IVIG,
Intravenous Immunoglobulin; NAbs-Aβ, natural occurring polyclonal Anti-Aβ antibodies).
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phospho-tau) were found. ARIA, seizures and deaths
occurred more frequently [41-43]. However, by subse-
quent pooling of non-carrier patients with very mild AD
across the studies potential treatment benefits in dis-
ability assessment score were achieved, implying that an
earlier treatment in the pathogenesis might be useful.
AAB-003/PF-05236812 is a humanized 3D6 (i. e.
Bapineuzumab) with mutations in the Fc domain [56] to
reduce effector functions and thereby ARIAs. Therefore,
an improved clinical safety profile of AAB-003 comparedto Bapineuzumab could be expected. Currently two clin-
ical Phase I trials are ongoing to evaluate the safety and
the tolerability of AAB-003.
Solanezumab (m266) recognizes a linear epitope in the
centre of Aβ and therefore does not bind any larger Aβ-
aggregates [60]. Therefore, the only conceivable mecha-
nisms of actions for Solanezumab are peripheral sink
and sequestration. The mAb also failed some weeks later
than Bapineuzumab in Phase III in two clinical trials to
meet its primary cognitive and functional endpoints
[61,62]. Surprisingly, in a secondary analysis a reduction
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after switching the cognition score, again implying that
earlier treatment could be beneficial. There were no
changes noted in biomarkers such as tau, phospho-tau,
hippocampal volume, whole brain volume, or amyloid ac-
cumulation [44]. The sponsors are apparently not discour-
aged by the data and continue the clinical development of
Solanezumab in an open-label extension study.
Gantenerumab (RO4909832 or R1450) is a fully hu-
man mAb that recognizes the N-terminal and the cen-
tral region within Aβ [47,48]. The binding profile of the
mAb was engineered by in vitro maturation on fibrillar
Aβ, resulting in a mAb that binds Aβ monomers and fi-
brils, conformed by x-ray diffraction. In addition, it was
described, that Gantenerumab neutralizes Aβ42 oligo-
mers. These oligomers, however, were pre-treated with
HFIP and diluted in Tris-buffer resulting in a mixture of
LMWO and higher aggregates to our knowledge [28],
therefore oligomer-specificity has yet not directly been
shown. In a Phase I clinical trial, Gantenerumab reduced
cerebral amyloid, but also ARIA were observed. The hu-
man mAb is currently in Phase III.
GSK933776 is a humanized mAb directed against the
N-terminus of Aβ, believed as linear epitope [55]. The
Fc domain of GSK933776 was mutated to reduce the
risk for vasogenic edema. Development for AD was
discontinued after Phase I in 2011.
The so-called second generation of anti-Aβ mAbs is in
development to target pathogenic Aβ multimers rather
than Aβ monomers or fibrils. However, as already men-
tioned the prefibrillar Aβ-preparations are usually not
well defined making it difficult to judge the recognized
pathogenic species. Moreover, since binding studies for
characterization are usually performed in an ELISA-like
assay with the full IgG, it is not clear whether affinity or
avidity was measured.
BAN2401 is the humanized mAb158 derived from
mice immunized with protofibrils derived from the arc-
tic mutation of Aβ42. Arctic Aβ is not able to fibrillize
and thus remains prefibrillar [63]. BAN2401 was the first
mAb believed to selectively bind, neutralize and elimin-
ate protofibrils. Nevertheless, affinity for other aggregate
species than protofibrils cannot be ruled out since the
primary characterization of the here applied aggregates
is based on SEC data revealing a peak at the exclusion
limit of the used column. This peak might comprise a
broad range of aggregates larger than 60 kDa. Their
ELISA data give rise for an antibody, which is rather
specific for prefibrillar and fibrillar Aβ. BAN/mAb158 is
being evaluated in clinical Phase II.
Crenezumab (MABT5102 or RG7412) was derived by
immunization with modified Aβ1-15 [52], containing a hu-
man IgG4 backbone to reduce effector function [64-66].
MABT5102A is supposed to target multiple conformationalprotofibrillar epitopes of Aβ, including oligomeric forms,
while inhibiting aggregation and promoting disaggregation
of Aβ [67]. Though, having a closer look at the preparation
of the Aβ42 aggregates, this appears rather an empiric than
a defined preparation. The only characterization method
for the Aβ preparation was SDS-PAGE and controls or
head-to-head comparison with other mAbs were missing in
the activity assays. A Phase I clinical trial proved safety,
Phase II is ongoing.
SAR228810 was derived from 13C3 by immunization
with polymerized synthetic Aβ42 peptide while the
degree of fibrillar Aβ42 content was monitored by circu-
lar dichroism spectroscopy [57,68]. The immunogenic
peptide was thereby rather well defined. 13C3 is there-
fore believed to recognize a conformational epitope of
prefibrillar Aβ aggregates. The humanized 13C3 is in
clinical Phase I evaluation.
BIIB037/BART is a novel fully human IgG1 and was
generated using a reverse translational medicine approach
screening endogenous anti-Aβ antibodies from an AD pa-
tient with an unusual stable clinical course [58]. BART ap-
parently shows a high affinity/avidity for insoluble fibrillar
Aβ and a 100-fold decreased affinity for Aβ monomers.
The applied Aβ-preparation for characterization of this
antibody comprises a broad range of aggregates and the
terminus fibrillar is not well defined. Thus, it is not
surprising that BART reveals substantially identical af-
finity to monomeric and fibrillar Aβ since it is specific
for any Aβ-aggregate species [69]. In APP transgenic
mice BART reduced amyloid burden while Aβ plasma
increase was not observed. Microglia appeared to play a
pivotal role in clearing plaques [70]. A Clinical Phase I
trial is currently ongoing.
Aβ20-42 globulomers, a condensed and hydrophobic
oligomer in presence of 0.2% SDS, were used for
immunization to develop the mAb A-887755 that is sup-
posed to differentiate Aβ globulomers from all other Aβ
species, especially monomers and fibrils [71,72]. But
again, the characterization was based on SEC, WB, thus
not allowing for a definition of the Aβ-aggregate species.
Nevertheless, A-887755 has high affinity/avidity for
immobilized Aβ20-42 globulomers and detects endogen-
ous Aβ species but not in non-demented age-matched
control patients nor in vascular Aβ deposits. A-887755
was characterized in preclinical studies and has yet not
been advanced to the clinic.
To summarize, many different aggregation protocols
have been applied to generate Aß-aggregates for immu-
nization resulting in a broad range of applied Aß-species.
Taking into account that the applied species have a transi-
ent nature, the fate after injection is not clear and thus the
effective antigen as well not. Furthermore, the terms used
for the definition of Aβ-aggregate species are still not co-
herent and hamper any comparison.
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ical efficacy of anti-Aβ mAbs in ‘ordinary’ clinical trials,
since early diagnosis based on CSF and imaging bio-
markers for a successful treatment with disease modify-
ing drugs has still not been achieved. One – probably
last – chance would be preventive trials in familial AD
cases that were currently started with Crenezumab.
Remarkably, efficacy will be tested in a five-year preven-
tion trial in an extended Columbian family carrying an
AD-related mutation, which causes early onset AD [73].
Moreover, the “Dominantly Inherited Alzheimer's Net-
work”, DIAN, will launch clinical trials with Solanezumab
and Gantenerumab soon in large families with genetic
mutations that make them susceptible to the disease [45].
Naturally anti-Aβ antibodies and IVIG treatment:
is polyclonal the key?
Polyclonal naturally occurring autoantibodies against Aβ
(NAbs–Aβ) are found in serum of healthy persons and
are reduced in AD patients [74-76]. Intravenous immu-
noglobulins, i.e. IVIGs, are commercially available as
polyclonal Ig preparations purified from human plasma
and are authority-approved for the treatment of im-
munosuppression, autoimmunity and a variety of other
neurological conditions. IVIG contains NAbs–Aβ and
interestingly, regular IVIG treatment reduced the risk of
developing AD by more than 40% in these patients [77].
Moreover, NAbs–Aβ seem to inhibit the propensity of
Aβ to aggregate, thereby blocking its toxicity, and af-
fected the clearance of Aβ, but NAbs–Aβ did not readily
clear senile plaques although early fleecy-like plaques
were reduced. [78]. In epitope mapping, NAbs–Aβ
detected mainly the mid-/C-terminal epitope of Aβ,
starting at the amino acid 28. NAbs–Aβ are believed to
preferentially capture apparent dimers and trimers and
interfere with oligomers [79,80], which were prepared as
described from Kayed et al. [24]. It is hypothesized that
NAbs–Aβ rather recognize a common conformational
epitope than a distinct peptide sequence [81]. In active
Aβ immunization studies in AD patients, fibrillar Aβ42
was used as an antigen, suggesting that N-terminal epi-
topes of the Aβ peptide were predominantly exposed
and were available as binding sites. Accordingly, active
immunization like AN-1792 generated primarily anti-
bodies that recognized the N-terminus [82]. Likewise,
Aβ peptide is deposited in a fibrillar form in the plaques,
and the N-terminal part of the Aβ peptide is mostly
available at the plaque surface. In contrast, NAbs–Aβ,
mainly directed to the central and C-terminal epitopes
of Aβ, are less capable of binding the N-terminus of Aβ;
thus NAbs–Aβ do not clear plaques.
In different clinical pilot studies [76,83,84], IVIG af-
fected plasma Aβ, improved cognition and the amount
of Nabs-Aβ in patient’s serum increased dose-dependentlywith IVIG treatment. However, those trials did not have
strong statistical significance. In a subsequent small Phase
II study, IVIG exhibited a dose-dependent effect on brain
atrophy [85] that was assumed to be correlated with
improvement in clinical outcomes [86]. Preliminary data
released in summer 2012 [49,50] showed a three-year
stabilization of AD symptoms with IVIG, including no de-
cline in cognition, memory, daily functioning and mood.
The patient number involved is rather small: out of 16 pa-
tients who completed the open-label three-year follow-up,
four patients receiving the most effective dose were princi-
pally unchanged from their cognitive baseline. A recently
completed study using IVIGs from another manufacture
has not met its primary endpoints in improving or stabil-
izing cognition [51]. Conversely to previous studies, no
changes in plasma and CSF Aβ could have been detected
during the treatment. The only apparent benefit of the
treatment was a significant improvement in cerebral glu-
cose metabolism.
Several Phase II and III trials of IVIG in AD are cur-
rently ongoing. Meanwhile, the sponsors of the largest
current trials are less optimistic to achieve endpoints in
mild-to-moderate AD [87]. While IVIG could apparently
demonstrate a positive signal in early AD, the effects on
cognition are unlikely to be statistically significant in
more advanced AD. Possibly, the previous results from
small cohorts included patients early in AD pathogenesis
and are therefore not comparable with the studies from
Bapineuzumab and Solanezumab. Finally, in geriatric pa-
tients the use of IVIG is often limited by renal insuffi-
ciency [88] and we would not have enough blood donors
to supply all upcoming AD patients with IVIG [89] in
case that Phase III trials give positive results.
Conclusion
To summarize, the reported and potentially relevant Aβ-
aggregates range from the smallest possible aggregate –
the dimer – up to particles with hundreds of kDa. Fur-
thermore, all of these reveal neuronal impairment in AD
models. Including the many reported methods for Aβ-
aggregate preparation one might question whether the
whole spectrum of prefibrillar Aβ-aggregates is of rele-
vance in AD and that some Aβ-aggregative species might
share conformational motifs exerting pathophysiological
effects [90]. Possibly, the ongoing polymerization process
promotes Aβ-related neurotoxicity [91] via many transient
aggregate intermediates. In addition, most of the described
Aβ-aggregates are not covalently bound and reveal re-
markable meta-stability, with the ability for reorganization
within different aggregate equilibria [11,17,28]. It is
conceivable that commonly used methods for Aβ
characterization provide only an isolated view of individ-
ual Aβ-species as opposed to the entire spectrum of Aβ-
aggregates. This also has implications for immunization
Moreth et al. Immunity & Ageing 2013, 10:18 Page 7 of 9
http://www.immunityageing.com/content/10/1/18with Aβ-aggregates, since their fate after injection is en-
tirely elusive owing to their transient nature.
Therefore it might be a long run to define a species as
well as to pick out the corresponding antibody. There
might be a conservative conformation shared by pre-
fibrillar aggregates, which could be identified as promis-
ing target, however this is still elusive. We assume that
explicitly hunting for conformation specific monoclonal
antibodies is less promising than depleting whole Aβ
from the brain with a polyclonal approach unless the
toxicity-mediating motif has been identified. Polyclonal
IVIGs appear to recognize more than one species of Aβ,
which would probably explain why patients treated with
IVIGs for immunological indications have a reduced risk
to develop AD.
From the regulatory point of view, the approval of a
highly innovative active substance for the treatment for
AD still remains a challenge. Although, biomarker strat-
egies have been more and more taken into account, the
current study designs for AD superficially address the si-
lent pathogenesis of the disease. Hence, meta-analysis of
current clinical trials confirms that preventive ap-
proaches might be the right tool to avoid the onset of
AD. Furthermore the selection of a geriatric-friendly ap-
plication form might play an important role with respect
to a “total compliance”. Therefore, it might be the more
promising strategy to approach the whole spectrum of
Aβ aggregates rather than to focus on a distinct aggrega-
tive species by acute treatment, thus, to generally dimin-
ish Aβ by means of a control-released immunotherapy
suitable for a geriatric population. Possibly, IVIG or the
translational medicine approach can support the hunt
for the one toxic species of Aβ as it seems that we have
the key in our plasma, recognizing pathogenic proteins.
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